# REVA Medical

> REVA Medical, LLC is a privately held San Diego medical-device company developing and commercializing bioresorbable polymer technologies and implantable vascular devices, including coronary and below-the-knee scaffolds and embolic beads.

Company page on Leadbay: https://mad-max.leadbay.ai/company/revamedical.com · loaded 2026-10-29

## At a glance

- Website: https://revamedical.com
- Team based in: San Diego (Leadbay's record and 2 more)
- Incorporated: California (no. 202005510352) (register)
- Registry: California Secretary of State 202005510352
- Founded: 1998 (linkedin.com and 2 more)
- Founders: Robert Stockman
- Industry: Medical Device
- Employees: 50 (employees and founders, investors not counted; revamedical.com and 1 more)
- Total funding: $146.6M (revamedical.com and 1 more)
- Backed by: BioStar Capital, Unnamed global strategic medical-device investor, Existing investors, Domain Associates, Medtronic, Bain Capital Public Equity, Cerberus Capital Management, Boston Scientific, Elliott Management
- Seen in its site's code: LinkedIn Insight (snap.licdn.com/li.lms-analytics), WordPress (/wp-content/), Microsoft 365 (MX revamedical-com.mail.protection.outlook.com), Salesforce (TXT include:_spf.salesforce.com) (read 2026-10-30)
- Phone: (858) 966-3000
- Email: info@revamedical.com
- Address: 5751 COPLEY DR STE B
SAN DIEGO, CA 92111-7912

## What it sells, to whom

- REVA Medical, LLC is a privately held San Diego medical-device company developing and commercializing bioresorbable polymer technologies and implantable vascular devices, including coronary and below-the-knee scaffolds and embolic beads. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))

## Why it stands out

- Competes with: Xtenti, Efemoral Medical, Broncus Medical, Endologix, Sahajanand Laser Technology, Japan Medical Device Technology, Hartlon, Abbott (historical competitor in bioresorbable scaffolds), Boston Scientific (historical competitor/partner in bioresorbable scaffolds) ([cbinsights.com](https://www.cbinsights.com/company/reva-medical-inc), [tracxn.com](https://tracxn.com/d/companies/revamedical/__G7FarQUH3IlIPxHsHgGDvXJGAq4y6K88jTEc8GjG6BY), [mddionline.com](https://www.mddionline.com/cardiovascular/life-after-bankruptcy-reva-returns-with-funding-raise))

## Products and services

- **Fantom Encore**: drug-eluting, Tyrocore-based bioresorbable coronary vascular scaffold; commercially available in select European countries. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))
- **Fantom**: earlier-generation bioresorbable coronary vascular scaffold. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))
- **MOTIV**: sirolimus-eluting bioresorbable scaffold for below-the-knee peripheral artery disease; CE Mark availability is stated for select markets, while U.S. use remained investigational in the provided 2026 results. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))
- **TyroSphere**: bioresorbable, potentially radiopaque embolic microspheres for hypervascular tumors; U.S. FDA clearance was still a development objective in the 2022 source. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))
- **Tyrocore**: proprietary tyrosine-derived bioresorbable polycarbonate polymer platform used in the company’s vascular devices. ([revamedical.com](https://www.revamedical.com/our-company/), [revamedical.com](https://www.revamedical.com/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html))

## Customers and markets

- **Customers**: Hospitals and interventional physicians treating coronary and peripheral artery disease; specific named end customers were not identified., HealthLink Europe BV is identified as the order-placement/customer-inquiry contact and distributor channel in Europe. ([revamedical.com](https://www.revamedical.com/our-company/), [sec.gov](https://www.sec.gov/Archives/edgar/data/1496268/000119312520062143/d887965dex991.htm), [revamedical.com](https://www.revamedical.com/contact/))
- **Markets**: Europe and other select countries accepting CE Mark are the current commercial markets identified for MOTIV; the brochure specifically says MOTIV is available in select CE-Mark countries. ([prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-successful-motiv-live-case-demonstration-and-late-breaking-btk-trial-results-at-viva26-302900013.html), [revamedical.com](https://www.revamedical.com/), [revamedical.com](https://www.revamedical.com/wp-content/uploads/2026/04/REVA-Medical-MOTIV-Brochure-Website.pdf))
- **Markets**: The U.S. is a development/regulatory market for MOTIV, not a current sales market: the device is investigational and limited by U.S. federal law to investigational use. ([prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-successful-motiv-live-case-demonstration-and-late-breaking-btk-trial-results-at-viva26-302900013.html), [revamedical.com](https://www.revamedical.com/), [revamedical.com](https://www.revamedical.com/wp-content/uploads/2026/04/REVA-Medical-MOTIV-Brochure-Website.pdf))

## Team

- Robert Schultz, President
- Robert Stockman, Founder
- Jessica Earley, CTO
- Douglas Henson, Director of Accounting and Administration
- Naomi Gong, Vice President Regulatory Affairs QA
- Vipul Taneja, Sr. Director, Operations
- Terrie Heidemann, Director of Quality Assurance

Backed by: BioStar Capital, Unnamed global strategic medical-device investor, Existing investors, Domain Associates, Medtronic, Bain Capital Public Equity, Cerberus Capital Management, Boston Scientific, Elliott Management

## Latest news

- 2026-04-29 · [Reva Medical’s MOTIV BTK Trial Meets Primary Efficacy Endpoint - Endovascular Today](https://c4v8.evtoday.com/news/reva-medicals-motiv-btk-trial-meets-primary-efficacy-endpoint) (c4v8.evtoday.com)
- 2026-04-21 · [REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia](https://www.prnewswire.com/news-releases/reva-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748107.html) (prnewswire.com)
- 2022-08-09 · [REVA MEDICAL ANNOUNCES CLOSING OF STRATEGIC FINANCING](https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html) (prnewswire.com)

## Where to find more

- [This page in Markdown, for agents](https://mad-max.leadbay.ai/company/revamedical.com.md)

## Decision makers

- [Robert Schultz](https://mad-max.leadbay.ai/person/robert-schultz--revamedical.com.md), President
- [Robert Stockman](https://mad-max.leadbay.ai/person/robert-stockman--revamedical.com.md), Founder
- [Jessica Earley](https://mad-max.leadbay.ai/person/jessica-earley--revamedical.com.md), CTO
- [Douglas Henson](https://mad-max.leadbay.ai/person/douglas-henson--revamedical.com.md), Director of Accounting and Administration
- [Naomi Gong](https://mad-max.leadbay.ai/person/naomi-gong--revamedical.com.md), Vice President Regulatory Affairs QA
- [Vipul Taneja](https://mad-max.leadbay.ai/person/vipul-taneja--revamedical.com.md), Sr. Director, Operations
- [Terrie Heidemann](https://mad-max.leadbay.ai/person/terrie-heidemann--revamedical.com.md), Director of Quality Assurance

Work emails and direct phones come with a Leadbay account: https://wow.leadbay.ai/?register=true

Where it comes from: 14 sites read (revamedical.com, prnewswire.com, sec.gov, cbinsights.com, tracxn.com, mddionline.com, c4v8.evtoday.com, cacompanyregistry.com, …).

## Best angle

2026-09-01 · Traffic: Site visits up 131% in 3 months, 5,118 a month (1 source)

## Best way in

- Call the front desk, (858) 966-3000: The front desk, in Leadbay's record, verified 2026-10-22
- Message on X: The company's own account
- Write to info@revamedical.com (generic): A shared mailbox, in Leadbay's record, verified 2026-10-22

## Signals: what happened

- 2026-10-06 · News: Post by REVA Medical, LLC. (2 sources: [linkedin.com](https://www.linkedin.com/posts/reva-medical-inc%2E_reva-medical-announces-successful-motiv-activity-7513272989254160384-PJSW), [linkedin.com](https://www.linkedin.com/posts/cgxp-wire_revamedical-motiv-viva26-activity-7513884407708110848-ZkMn))
- 2026-10-06 · News: The live case demonstration of our MOTIV device was a complete success at (1 source: [linkedin.com](https://www.linkedin.com/posts/savinosguera86_reva-medical-announces-successful-motiv-activity-7513372282346479617-TP57))
- 2026-09-01 · Traffic: Site visits up 131% in 3 months, 5,118 a month (1 source: [A company database](https://www.revamedical.com/))
- 2026-04-29 · News: Reva Medical’s MOTIV BTK Trial Meets Primary Efficacy Endpoint (1 source: [c4v8.evtoday.com](https://c4v8.evtoday.com/news/reva-medicals-motiv-btk-trial-meets-primary-efficacy-endpoint))
- 2026-04-21 · Product: REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia (2 sources: [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748107.html), [prnewswire.com](https://www.prnewswire.com/news/reva-medical%2C-llc/))
- 2026-04-21 · News: At Charing Cross, Dr. Wittig presented late-breaking data from the MOTIV-BTK Pivotal Trial, focusing on primary safety and effectiveness outcomes. (1 source: [linkedin.com](https://www.linkedin.com/posts/reva-medical-inc%2E_at-charing-cross-dr-wittig-presented-late-breaking-activity-7452326575603122176-Yi90))
- 2026-04-17 · News: We are pleased to be exhibiting at the Charing Cross International Symposium in London. (1 source: [linkedin.com](https://www.linkedin.com/posts/reva-medical-inc%2E_we-are-pleased-to-be-exhibiting-at-the-charing-activity-7450917148782223361-Oaoc))
- 2026-04-15 · News: My team here at REVA Medical, LLC. is looking for a new QC Lab Manager (so I can spend more hands-on time in the lab). Do you know anybody deeply experienced with … (1 source: [linkedin.com](https://www.linkedin.com/posts/savinosguera86_current-career-opportunities-at-reva-medical-activity-7450220051594641408-Of3W))
- 2026-03-18 · Hiring: We're growing at Reva Medical and currently hiring across several roles, with a strong focus on manufacturing and quality positions. (1 source: [linkedin.com](https://www.linkedin.com/posts/vipul-taneja-9a230217_current-career-opportunities-at-reva-medical-activity-7440127516872417280-Ckmp))
- 2025-09-23 · News: REVA reported positive 36-month MOTIV study results for below-the-knee artery disease (4 sources: [revamedical.com](https://www.revamedical.com/category/press-releases/), [prnewswire.com](https://www.prnewswire.com/news-releases/reva-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748136.html), [c4v8.evtoday.com](https://c4v8.evtoday.com/news/reva-medicals-motiv-btk-trial-meets-primary-efficacy-endpoint))
- 2025-04-23 · News: REVA Medical, LLC. reshared Matthias Lutz: 10 years after Scaffold implantation. One of the first patients in the II trial. Happy Easter!! (1 source: [linkedin.com](https://www.linkedin.com/posts/reva-medical-inc%2E_httpslnkdinge527vnf-activity-7320846799747829760-c_Br))
- 2024-05-09 · News: REVA Air Ambulance and Seaplane Medevac Operations (1 source: [doi.org](https://doi.org/10.1016/j.amj.2024.03.017))

## Working on now

- Primary focus is MOTIV, a sirolimus-eluting, bioresorbable scaffold for below-the-knee peripheral artery disease and chronic limb-threatening ischemia.
- The company is advancing MOTIV toward U.S. regulatory approval: its pivotal randomized BTK trial met safety and efficacy endpoints, while the product remains investigational and unavailable in the U.S.
- REVA is also supporting European commercial activity and long-term clinical evidence for MOTIV; its 36-month European post-market study reported 80% primary patency and 95% limb salvage.
- The underlying platform is Tyrocore, a radiopaque, bioresorbable polymer for vascular devices; the portfolio also includes Fantom Encore for coronary disease and TyroSphere embolic microspheres, but current 2026 communications center on MOTIV.

From: [REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26](https://www.prnewswire.com/news-releases/reva-medical-announces-successful-motiv-live-case-demonstration-and-late-breaking-btk-trial-results-at-viva26-302900013.html), [REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia](https://www.prnewswire.com/news-releases/reva-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748107.html), [Bioresorbable Polymers for Vascular Scaffolds | REVA](https://www.revamedical.com/), [REVA Medical Announces Positive 36-Month MOTIV Bioresorbable Scaffold Study Results for Below-the-Knee Artery Disease](https://www.einpresswire.com/article/851766701/reva-medical-announces-positive-36-month-motiv-bioresorbable-scaffold-study-results-for-below-the-knee-artery-disease)

## Summary

REVA Medical, LLC is a medical device company that develops and commercializes bioresorbable polymer technologies for vascular applications [1][2]. It sells its products, primarily bioresorbable scaffolds that disappear from the body over time, to medical providers for the treatment of coronary artery and peripheral artery diseases [1][3][2]. The company’s primary products are the Fantom Encore coronary scaffold and the MOTIV peripheral scaffold [2]. Its customers are interventional cardiologists and vascular specialists, while its major competitors include Abbott, Boston Scientific, and Medtronic [4]. In October 2026, the company reported positive late-breaking clinical results for its MOTIV scaffold at the VIVA26 conference [3].

[1]: https://www.revamedical.com/our-company/ "Our Company | REVA"
[2]: https://www.sec.gov/Archives/edgar/data/1496268/000119312520062143/d887965dex991.htm "EX-99.1"
[3]: https://www.prnewswire.com/news-releases/reva-medical-announces-successful-motiv-live-case-demonstration-and-late-breaking-btk-trial-results-at-viva26-302900013.html "REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26"
[4]: https://www.sec.gov/Archives/edgar/data/1496268/000110465915024024/a15-1762_110k.htm "sec.gov"
[5]: https://www.revamedical.com/category/press-releases/ "Press Releases Archives - REVA Medical"
[6]: https://www.prnewswire.com/news-releases/reva-medical-announces-closing-of-strategic-financing-301602899.html "REVA MEDICAL ANNOUNCES CLOSING OF STRATEGIC FINANCING"
[7]: https://revamedical.com/wp-content/uploads/2021/11/reva-bbraun-announcement.pdf "Shaping the future of vascular stenting – REVA"
[8]: http://www.revamedical.com/wp-content/uploads/2022/08/reva-medical-announces-closing-of-strategic-financing.pdf "in medical devices, as well as"

## Sources

- [Reva Medical, LLC's website](https://revamedical.com)
- [Bioresorbable Polymers for Vascular Scaffolds | REVA](https://www.revamedical.com/)
- [REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia](https://www.prnewswire.com/news-releases/reva-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748107.html)
- [REVA Medical Announces Positive 36-Month MOTIV Bioresorbable Scaffold Study Results for Below-the-Knee Artery Disease](https://www.einpresswire.com/article/851766701/reva-medical-announces-positive-36-month-motiv-bioresorbable-scaffold-study-results-for-below-the-knee-artery-disease)
- [REVA Medical, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo](https://system.privco.com/company/reva-medical-inc)